Komori
Dividends4527ROHTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Regarding Dividend of Surplus

The year-end dividend payable to shareholders of record as of 31 March 2026 was set at ¥25 per share, for a total of ¥5,649 million. The dividend per share increased by ¥5 from ¥20 in the previous fiscal year, but remains unchanged from the latest forecast of ¥25.

Worth reading
67In focus
Scored from 3 of 5 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
5
Yen/share
Wording
Definitive
How definitive the wording is.

Dividend per share

Fiscal year ending March 2026
25YenRevised annual dividend per sharePrevious forecast ¥25, change ¥0(0.0%)
Previous-period resultsPrevious forecastAfter revision

Each vertical step represents one dividend payment, and the total height of the accumulated steps represents the annual dividend for the period. For periods showing only the annual amount, the payment breakdown is not provided, so only the end point is plotted.

Total dividendsTotal amount payable to all shareholders¥4,519 million→¥5,649 million
Whether Submission to the General Meeting of Shareholders Is RequiredBoard of directors resolution only
Record date31 March 2026
Effective date8 June 2026

The record date is the cutoff date for determining which persons listed in the shareholder register on that date are entitled to receive dividends.Payments begin on the effective date.

Source of dividendsRetained earningsThe source of dividend payments. Depending on the type of surplus, the dividend may be paid from earned profits or may be closer to a return of capital.
Dividend per share
ItemDetails
Dividend per share¥25 → ¥25(0.0%)
Previous-period results (per share)Interim ¥16 / End of period ¥20 / Annual ¥36
Total dividends¥4,519 million → ¥5,649 million
Record date31 March 2026
Effective date8 June 2026
Source of dividendsRetained earnings
Whether Submission to the General Meeting of Shareholders Is RequiredBoard of directors resolution only
Fiscal Period CoveredFiscal year ending March 2026
Items this document does not state (4)
Total Annual DividendsBreakdown of Regular, Commemorative and Special DividendsPayout ratioDividend policy

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

No reason for determining the dividend is stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Dividend of Surplus | ROHTO PHARMACEUTICAL CO.,LTD. (4527) timely disclosure | Komori